GSK Picks Up RAPT for $2.2B as Miels Makes First Move as CEO

GSK is acquiring RAPT Therapeutics for $58 per share in cash in a deal valued at $2.2 billion (upfront net investment of roughly $1.9 billion after RAPT cash), sending RAPT stock up ~63.8% pre-market to $57.50. The purchase targets ozureprubart, a long‑acting anti‑IgE mAb dosed every 12 weeks being developed as a prophylactic for food allergies (Phase IIb prestIgE readout expected in 2027) and with positive urticaria data; the deal positions GSK to compete with Roche’s Xolair, which generated ~CHF2.23 billion (~$2.82 billion) in the first nine months of 2025. The acquisition comes three weeks into CEO Luke Miels’s tenure, underscoring management’s early strategic push into the food‑allergy market.

Analysis

Market structure: GSK’s $2.2bn buy of RAPT (net $1.9bn; $58/share) transfers a potential late-stage asset and immediate pipeline upside to a large-cap pharma with commercialization scale. Winners: GSK (pipeline expansion, potential to take share in food‑allergy biologics) and RAPT shareholders (cash-out near $58); losers: Roche (RHHBY) faces incremental competition for Xolair in a >$2.8bn annualized revenue pool and any independent small allergy biotech without scale. Cross-asset: modest near-term corporate credit spread widening for GSK is possible but limited; biotech volatility and equity options on GSK/RHHBY will rise into the 2027 readout window; FX/commodities negligible.

Risk assessment: Tail risks include Phase IIb/registrational failure in 2027, unexpected safety/immunogenicity for long‑acting anti‑IgE, or payor refusal to reimburse at price points that sustain premiums—each could wipe >$2bn of implied asset value. Immediate (days): deal closing/legal review; short-term (weeks–months): integration and messaging on label strategy; long-term (to 2027): clinical readout is binary. Hidden dependencies: success depends on payer economics vs Xolair’s established position and on manufacturing scale for 12‑week dosing.

Trade implications: Favor event-driven, asymmetric exposure to GSK upside into the 2027 Phase IIb readout while hedging clinical/regulatory binary risk. Direct plays: modest long GSK exposure via defined-cost call spreads or LEAPs; relative trade: long GSK vs short RHHBY to express potential market-share transfer. Use short-dated options to harvest elevated IV ahead of quarterly results and long-dated options to capture 2027 outcome; size conservatively (1–3% portfolio).

Contrarian angles: Consensus assumes dosing convenience equals displacement of Xolair; payor inertia and Roche’s entrenched clinical data and relationships can blunt uptake—displacement is neither immediate nor guaranteed. The market may underprice regulatory/coverage risk and overprice convenience as a monopoly breaker; historical parallels (category incumbents retaining share despite new entrants) suggest a multi-year commercial fight, not instant market flip. Unintended consequence: GSK may face higher launch costs and pricing concessions that compress near‑term ROI.

Key Decisions for Investors

• Establish a 1–1.5% portfolio long position in GSK (ticker GSK) via a 12‑month call spread to cap cost: buy 12‑month 10% OTM calls and sell 12‑month 40% OTM calls (or equivalent delta structure). Target hold through the 2027 Phase IIb data; take profits if position rises +30–50%; cut to half size on a 20% drawdown.
• Implement a pair trade expressing relative strength for GSK vs Roche: long GSK 1.0% funded by short RHHBY (or buy 6–9 month RHHBY put spread) sized 0.5% portfolio. Reassess after Roche quarterly report or earlier if Xolair guidance deviates by >5% vs consensus.
• Avoid directional exposure to RAPT common stock; only engage as arb if the spread to $58 exceeds $0.50 and deal terms confirm cash-only and no regulatory condition (expected close window: next 30–90 days). Otherwise, allocate remaining allergy‑theme risk budget to option structures on GSK expiring into 2027 readout (buy-dated LEAP calls capped with call-sell wings).